RDi announces CEO appointment

LONDON – June 25 2024 – RDi, the leading provider of healthcare and pharma services solutions for patient sample collection, today announced the appointment of David Cahill as Chief Executive Officer. David will lead the business as it builds upon its growing footprint in the healthcare market as the leading supplier of screening, diagnostic and patient-centric test kit solutions.

David brings to RDi over 25 years of experience in healthcare, life sciences and the pharma industry. His most recent role was as Chief Commercial and Strategy Officer for Alliance Medical, a leading diagnostics provider where he led the partnership delivery to both private and NHS customers. This included leading the development of several Community Diagnostics Centres, delivery of the NHS PET-CT contract, as well as leading Radiopharmaceutical production across the UK.

“We are delighted to welcome David as our new CEO”, said RDi Chairman, Martin Hiscox. “He brings with him many years of experience in healthcare alongside a proven track record of leadership and proposition development. With RDi innovating the remote self-sampling market, David is well placed to drive us on to the next phase in our ambitions.”

“David has fantastic diagnostics experience which coupled with his proven success at driving expansion and growth see him coming on board to lead RDi at a pivotal time,” said Chris Tagg, Chief Strategy Officer of RDi. “We have been on a journey that has seen us drive the business into the emerging virtual healthcare sector and having David’s knowledge, capabilities and support will be a major asset in enabling us to complete that journey.”

“I am thrilled to be joining RDi at this truly exciting phase of their journey,” added David. “RDi has proven, large-volume solutions already in the marketplace changing the way that patients can provide samples for screening and diagnostics. I have been hugely excited by the potential to further transform access to healthcare for patients through areas such as clinical trials and screening. There is a great deal of potential for RDi and its innovative products. I am looking forward to working with the amazing team and our clients to support and expedite the solutions that are currently in such demand.”

Discover more about RDi here.

Share the Post:

Related Posts

Thank you for your enquiry

The RDi Team will be in contact shortly